Product treats susceptible strains of common pathogens found in canine otitis externa
A new veterinary-administered product that treats canine otitis externa with a single dose is set to hit the UK market early next year.
Bayer Animal Health’s Neptra ear drops solution for dogs has received marketing authorisation for use in Europe and will be available in early 2020.
The product is approved for the treatment of acute canine otitis externa, or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol and fungi sensitive to terbinafine.
Mario Andreoli, head of marketing at Bayer Animal Health, said: “Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian. Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice.”
Bayer said that the product requires no at-home applications by the dog owner, keeping the treatment in the hands of the veterinary surgeon and allowing full control over compliance.
Andreoli continued: “With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application.”
Image (C) Bayer Animal Health.
Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.
